InspireMD announced that the Company has appointed principal investigators for its upcoming C-GUARDIANS II clinical trial of the SwitchGuard Neuroprotection System. Patrick Geraghty, M.D., professor of surgery and radiology, section of vascular surgery at Washington University School of Medicine in St. Louis, MO, and Patrick Muck, M.D., program director and chief of vascular surgery at Good Samaritan Hospital in Cincinnati, OH, have enthusiastically agreed to act as lead PIs for the trial. Additionally, William Gray, M.D., system chief of the cardiovascular division at Main Line Health in Wynnewood, PA and professor of medicine at Thomas Jefferson University in Philadelphia, PA, will act as an advisor to the Company. The C-GUARDIANS II study is intended to advance clearance of SwitchGuard(TM) NPS and associated tools, designed to allow the treating physician to reverse cerebral blood flow during a TCAR procedure, thus preventing embolic debris generated during the procedure from traveling to the brain, passing the blood through the filter housed within the SwitchGuard(TM) before returning it to the patient to minimize blood loss.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NSPR:
- InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System
- InspireMD Secures CE Mark Recertification Under New EU Standards
- InspireMD Announces CE Mark Recertification Under MDR
- InspireMD receives CE Mark recertification under E.U.’s new MDR framework
- InspireMD appoints Pete Ligotti as EVP, GM of North America
